15.09.2014 • News • Bayer • Boston Scientific • Diabetes Care

Bayer Completes Sale of Interventional Device Business

Bayer HealthCare has completed the sale of its interventional device business to Boston Scientific for $ 415 million.

The German company said the divestment will allow its medical care division to concentrate on innovation and growth in radiology and diabetes care, where it already has a strong presence.

The transaction includes the AngioJet (thrombectomy) and Jetstream (atherectomy) systems, and the FetchAspiration catheter used in cardiology, radiology and peripheral vascular procedures.

Bayer's Interventional business had sales of $120 million in 2013.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Top-Feature

most read

Photo
28.07.2025 • News • Chemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.